Our study should also be differentiated from previous studies that have reported robust germinal centre responses and higher antibody titres against HIV through osmotic pump‐enabled slow delivery immunization technology,[64] in that we suggest an engineered biomaterial‐based metronomic‐like delivery technology that enables the generation of antigen‐specific effector CD8+ T cells and the reprogramming of the immunosuppressive TME, which are essential for the success of cancer immunotherapy. The gene discussed is CD8A; the disease is cancer.